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Abstract Binding of polyclonal and monoclonal antibodies,
quantitated by enzyme-linked immunosorbent assay, to porcine
SP-B reconstituted in different phospholipid bilayers has been
used to assess differences in protein structure due to lipid^protein
interactions. SP-B bound significantly more antibodies when it
was reconstituted in bilayers made of anionic phospholipids
(phosphatidic acid, cardiolipin, phosphatidylglycerol, phosphati-
dylinositol or phosphatidylserine) than in zwitterionic bilayers
(phosphatidylcholine, phosphatidylcholine/cholesterol, or phos-
phatidylethanolamine) or in fatty acid micelles (made of salts of
palmitic or stearic acids). These differences in immunoreactivity
can be important in the development of quantitation methods
for SP-B in clinical samples based on immunological tech-
niques. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Total or partial de¢ciency of pulmonary surfactant protein
SP-B results in impaired respiratory function [1,2] and severe
respiratory failure that is lethal in cases of total lack of func-
tional protein due to either genetic inactivation [3,4] or block-
age of the protein by anti-SP-B antibodies [5,6]. The working
hypothesis is that SP-B is essential for assembly, packing,
secretion and restructuration in the airways of a surface active
material, known as pulmonary surfactant, the main function
of which is to reduce surface tension at the air/water interface
of alveoli to very low values and so facilitate respiratory me-
chanics [7,8]. Surface activity resides principally in the phos-
pholipid moieties of this complex and especially in a disat-
urated phosphatidylcholine (PC) species, dipalmitoylphos-
phatidylcholine (DPPC). Proteins such as SP-B and the hy-
drophobic lipopeptide SP-C facilitate transfer of the surface
active phospholipids from the bulk of the aqueous alveolar
lining into the interface where they form ¢lms able to achieve
very low surface tension during exhalation [8,9]. Extensive
analyses of lipid^protein interactions of SP-B in surfactant
bilayers and monolayers have led to some comprehension of
SP-B function from a molecular point of view [10], but we are
still far from a full understanding of the essential role of the
protein in the intracellular assembly and packing of surfactant
bilayers. SP-B is thought to be necessary in vivo to promote
insertion of phospholipids at the interface, an activity it pro-
motes in vitro. A signi¢cant fraction of surfactant phospho-
lipids, around 8^10% by weight, are negatively charged species
at physiological pH, phosphatidylglycerol (PG) in most ani-
mals or phosphatidylinositol (PI) in some. Interactions of SP-
B with anionic phospholipids in surfactant seem to participate
in important processes in surfactant dynamics such as tubular
myelin formation [11,12], interfacial adsorption [13,14], re¢n-
ing of surface ¢lms upon compression [15] or stabilization of
compressed states of the ¢lms [16,17]. In the present work, we
have explored structural features induced by negatively
charged membranes into SP-B, analyzing possible di¡erences
in accessibility of the protein to polyclonal or monoclonal
antibodies when it was reconstituted into either zwitterionic
or anionic bilayers.
2. Materials and methods
2.1. Materials
Chloroform (Chl) and methanol (MeOH) were high performance
liquid chromatography-grade solvents from Scharlau (Barcelona,
Spain). Sephadex LH-20 and LH-60 chromatography gels were
from Pharmacia (Uppsala, Sweden). Egg yolk PC, PG, phosphatidyl-
ethanolamine (PE) and phosphatidic acid (PA), bovine liver PI, bo-
vine brain phosphatidylserine (PS), bovine heart cardiolipin (diphos-
phatidylglycerol, DPG), cholesterol (Ch), and palmitic (Pal) and
stearic (Ste) acids were all from Sigma (St. Louis, MO, USA).
DPPC and dipalmitoylphosphatidylglycerol (DPPG) were purchased
from Avanti Polar Lipids (Birmingham, AL, USA). Radiolabelled
1,2-di[1-14C]palmitoyl-L-3-phosphatidylcholine (112 Ci/mol) was
from Amersham International (Little Chalfont, Bucks, UK). Sub-
strates for enzyme immunoassays, 3-dimethyl aminobenzoic acid
(DMAB) and 3-methyl-2-benzothiazolinone hidracine (MBTH), were
also from Sigma. All other reagents and chemicals were from Merck
(Darmstadt, Germany).
2.2. Protein and lipid^protein samples
Surfactant proteins SP-B and SP-C were isolated from minced por-
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cine lungs by an adaptation of the method of Curstedt et al. [18],
which is described elsewhere [19]. SP-A was puri¢ed from porcine
lung lavages as described [20]. Purity of protein preparations was
routinely checked after isolation by SDS^PAGE and matrix-assisted
laser desorption ionization-time of £ight mass spectrometry, and the
protein concentration determined by amino acid analysis. Solutions of
puri¢ed SP-B and SP-C in Chl/MeOH (2:1, v/v) and SP-A in bu¡er
Tris^HCl 5 mM pH 7.4 were stored at 320‡C until use. To recon-
stitute SP-B in phospholipid bilayers, the proper amounts of protein
and the given lipid were ¢rst mixed as Chl/MeOH (2:1, v/v) solutions
and evaporated to dryness under a N2 stream. Afterwards, 50 mM
HEPES bu¡er pH 7 containing 150 mM NaCl was added and the
samples were allowed to hydrate for 1 h at a temperature above the
phase transition temperature of the corresponding lipid, namely at
room temperature (PC, PE, PG, PI, PS, PA, DPG, PC/Ch) or 50‡C
(DPPC, DPPG), whereupon they were dispersed by extensive sonica-
tion with a Branson UPS-2000 tip-soni¢er to form lipid^protein
vesicles. The conditions selected for sonication produce unilamellar
vesicles of 130^160 nm with a polydispersity index of around 0.2 in
di¡erent phospholipids, as determined by quasi-elastic light scattering
in an Autosizer IIc Photon Correlation Spectrometer (Malvern Instru-
ments) [20^22].
2.3. Antibodies
The anti-SP-B polyclonal antiserum used in the present study was
raised in New Zealand white rabbits by employing ¢ve intramuscular
inoculations scheduled every 7 days. A 100 Wg dose of SP-B recon-
stituted in micelles of lysophosphatidylcholine (LPC, 2:1 lipid to pro-
tein molar ratio by weight) in complete Freund’s adjuvant was used
for the ¢rst inoculation, and 70 Wg of protein in LPC micelles in
incomplete adjuvant was used in the subsequent doses. The inoculated
rabbit was bled 10 days after the last injection. The anti-SP-B poly-
clonal antiserum obtained following this protocol recognized SP-B but
not SP-A nor SP-C when it was used in Western blots.
Anti-SP-B monoclonal antibody 8B5E, recognizing an epitope of
human SP-B [23], was a generous gift of Dr. Yasuhiro Suzuki (Uni-
versity of Kyoto, Japan).
2.4. Enzyme-linked immunosorbent assay (ELISA)
The ELISA method used in this work was carried out as follows.
The wells of the plates (immunoplates Polysorp F96, Nunc A/S, Ros-
kilde, Denmark) were ¢lled with 100 Wl each of lipid or lipid^protein
suspensions prepared as described above and incubated at 4‡C over-
night. In a control experiment, the wells of the plates were coated by
evaporation at 37‡C of a methanolic SP-B solution. After protein,
lipid or lipid^protein coating, the wells of the microtiter plates were
washed six times with a solution of 0.05% (v/v) Tween-20 and blocked
for 1 h at 37‡C with 100 Wl each of 5% dried skim milk in phosphate-
bu¡ered saline (PBS) (137 mM NaCl, 10 mM Na2HPO4, 1.5 mM
KH2PO4, 2.6 mM KCl, pH 7.4). After washing six times with
0.05% Tween-20, an aliquot of 100 Wl of the primary antibody
(1/500 dilution of the polyclonal antiserum in PBS containing 0.05%
Tween-20) was added to each well and the plate was incubated for 1 h
at 37‡C. The plates were then washed again six times with 0.05% (v/v)
Tween-20, and incubated for 1 h at 37‡C with the secondary antibody,
peroxidase-labelled anti-rabbit IgG antibody (Amersham Internation-
al, Buckinghamshire, UK), that had been diluted 1/500 in PBS con-
taining 0.05% Tween-20. After washing six times, the plates were
developed by adding 200 Wl per well of the detection solution (80.6
mM DMAB, 1.56 mM MBTH, H2O2 0.0075% in 0.1 M phosphate
bu¡er pH 7). The reaction was stopped by the addition of 50 Wl of 1.5
M H2SO4. Results were assessed spectrophotometrically at 570 nm in
a Digiscan 340T microtiter reader (Asys Hitech Gmbh, Austria). Neg-
ative controls were always run, using an anti-SP-A polyclonal anti-
serum [24] as primary antibody to discount non-speci¢c signals.
The detection limit of this ELISA assay, under the conditions of
our experiments, was in the range 10^20 ng SP-B/ml (limit values were
8 ng/ml for SP-B in PG bilayers and 25 ng/ml for SP-B in PC bi-
layers). The coe⁄cient of interassay analytical variation was 7^8% in
all the assayed lipids (7 þ 3% for SP-B in PC vesicles, calculated from
19 independent determinations of samples containing 25^500 ng SP-B/
ml; 8 þ 3% for SP-B in PG vesicles, from 14 independent samples in
the range 8^250 ng SP-B/ml).
2.5. Statistical analysis
The experiments in this study have been repeated at least three
times, in each case using protein isolated from di¡erent surfactant
batches, and the results were qualitatively similar. Data plotted in
the ¢gures represent the mean of triplicate determinations þ S.D.
from a single protein batch. Student’s t-test was used to analyze the
di¡erence between the means. Di¡erences with a P value of 6 0.05
were considered statistically signi¢cant (**P6 0.01 and *P6 0.05 vs.
control).
3. Results
Fig. 1 compares immunoreactivity to anti-SP-B antibodies
of porcine SP-B reconstituted in zwitterionic (PC, DPPC) or
anionic (PG, DPPG) bilayers with that of the protein in the
absence of lipids. In general terms, when the protein was
embedded in membranes of PC, DPPC or DPPG its epitopes
were less recognized by polyclonal antibodies than in the ab-
sence of lipids, in the range of 1^100 ng SP-B per well. This
fact suggests that some of the epitopes are at least partly
shielded in the lipid^protein complexes. When a monoclonal
anti-SP-B antibody was employed (Fig. 1, right panel) SP-B
immunoreactivity was similar in the absence and in the pres-
ence of PC, DPPC or DPPG, suggesting that the epitope
Fig. 1. Binding curve of polyclonal (left panel) and monoclonal (right panel) primary anti-SP-B antibodies to porcine SP-B in the absence of
lipids (dashed lines) and reconstituted in phospholipid bilayers (solid lines) of di¡erent composition. SP-B protein to lipid ratio in the bilayers
was 1:20 by weight. Error bars represent standard deviation after averaging three di¡erent experiments. Those bars not shown are within the
symbol sizes.
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recognized by the antibody 8B5E is located in the exposed
parts of SP-B in the lipid^protein complexes. In DPPG bi-
layers, SP-B always showed higher binding of antibodies than
in bilayers made of PC or DPPC, although the di¡erences
were small. Interestingly, when SP-B was reconstituted in
vesicles of egg yolk PG, it bound much more of both anti-
bodies when tested either in the absence or presence of the
other lipids, suggesting that these negative membranes could
promote higher exposure of protein epitopes. The results were
very similar when comparing lipid^protein samples reconsti-
tuted at 1/10 and 1/20 SP-B protein to lipid ratio by weight
(not shown). Coating of ELISA wells with lipid vesicles, in the
absence of protein, did not produce any antibody binding to
any of the lipids tested, discounting artefacts due to direct
binding of anti-SP-B antibodies to these membranes. To en-
sure that di¡erences detected in antibody binding were not
caused by a di¡erent e⁄ciency of the protein/lipid systems
to adsorb to the plates during the coating procedure, we
quantitated the amount of material actually adsorbed onto
the wells by including a trace of 14C-labelled DPPC in the
di¡erent lipid^protein complexes. At di¡erent steps during
the coating and washing procedures, the wells were extensively
washed with Chl/MeOH (2:1, v/v) to recuperate all the ad-
sorbed lipids and quantitated by measuring 14C in a scintilla-
tion counter. Fig. 2 shows that there are some di¡erences in
the amount of material bound initially to ELISA plates, de-
pending on the lipid used to reconstitute the protein. The
amount of DPPC or DPPG vesicles initially adsorbed onto
the plates was about 30% lower than that of PC or PG
vesicles, suggesting that the membranes can enhance sample/
support interactions. However, the amount of material which
remained attached to the plates after the washing steps was
not signi¢cantly di¡erent among samples containing PC,
DPPC, PG or DPPG, con¢rming that the di¡erent amounts
of antibodies bound to the SP-B/lipid samples are most likely
explained as a consequence of di¡erences in the availability of
SP-B epitopes in the di¡erent membranes.
To determine if the greater exposure of SP-B epitopes in PG
vesicles is a speci¢c feature shown by SP-B in membranes
containing PG or a general e¡ect caused by negatively
charged membranes, we have tested and compared recogni-
tion of SP-B by antibodies after reconstitution of the protein
in bilayers made of di¡erent zwitterionic (PC, PE, PC/Ch 7%
by weight) or anionic (PG, PI, PA, PS, DPG) phospholipids
or in fatty acid anionic micelles (made of salts of Pal or Ste
acids). Fig. 3 shows that SP-B is more immunoreactive in all
the anionic membranes tested than in zwitterionic bilayers or
in anionic micelles such as those formed by the fatty acids.
Quantitative examination of the amount of antibodies bound
to SP-B reconstituted in the di¡erent lipids, in the linear por-
tion of the ELISA curve (Fig. 3c), indicated that the phos-
pholipid enhancement of SP-B immunoreactivity followed the
sequence
PSWPIWPGEDPGsPAsPEWPCWPC=ChWPalWSte
Statistical analysis of the di¡erences in immunoreactivity (Fig.
4) indicated that SP-B is signi¢cantly more immunoreactive in
all the anionic bilayers than in zwitterionic PC membranes.
Fig. 2. Phospholipid bound to ELISA plates coated with 50 ng of
SP-B in phospholipid vesicles (1:20 protein to lipid weight ratio),
before (B) and after (A) carrying out all the washing steps of the
ELISA procedure. Absorbed phospholipid amounts were calculated
by including in the lipid^protein samples a 14C-radiolabelled DPPC
trace. Error bars represent standard deviation after averaging three
di¡erent experiments.
Fig. 3. Binding curves of polyclonal anti-SP-B antibodies to porcine SP-B reconstituted in anionic (a) or zwitterionic (b) phospholipids or in
fatty acid micelles (also in b). c: Linear rescaling of plots at lower protein densities. Protein to lipid ratio was 1:20 by weight in all the sam-
ples. Error bars represent standard deviation after averaging three di¡erent experiments. Those bars not shown are within the symbol sizes.
FEBS 24782 9-4-01
J. Mar|¤a Oviedo et al./FEBS Letters 494 (2001) 236^240238
SP-B also bound signi¢cantly more antibodies in PG, PI or PS
bilayers than in PA membranes. We also detected a statisti-
cally signi¢cant lower binding of anti-SP-B antibodies to the
protein in stearate micelles, indicating a presumably unfavor-
able exposure of the protein epitopes in that environment.
4. Discussion
The results shown indicate that in anionic bilayers, pulmo-
nary surfactant protein SP-B assumes structural features
which lead to enhanced recognition by antibodies, in compar-
ison to protein included in zwitterionic bilayers. This e¡ect
could originate in a di¡erent conformation of the protein
being assumed as a consequence of electrostatic protein^lipid
interactions, which would then expose epitopes to a greater
extent. Alternatively, a higher SP-B antibody binding in neg-
atively charged membranes could be caused by a more favor-
able geometry of the lipid^protein complexes, for instance a
lower extent of penetration, and therefore less shielding, of the
SP-B protein into those bilayers as they are formed. Several
lines of evidence suggest that SP-B really has a more extended
conformation in negatively charged membranes. As deter-
mined by scanning calorimetry [25], the number of phospho-
lipid molecules perturbed per SP-B monomer upon interaction
with DPPC bilayers was lower, around 50, than those per-
turbed upon interaction with DPPG membranes, close to
70. On the other hand, SP-B has a substantially slower rota-
tional di¡usion coe⁄cient in DPPG than in DPPC bilayers,
which can only be explained by considering that the confor-
mation of the protein in anionic membranes gives rise to an
apparently larger rotation radius [26]. We have previously
determined that the extent of penetration of SP-B into
DPPC bilayers depends on the method used to reconstitute
lipid^protein complexes [27]. A similar study gives a compa-
rable penetration of SP-B into PC and PG bilayers, at least
with respect to the region of the protein where the single
tryptophan residue is located (results not shown). Whatever
its origin, the conformation/disposition of SP-B should be
considered in the context of selective interactions of the pro-
tein with the anionic phospholipids in pulmonary surfactant.
SP-B has shown a relative selectivity for interaction with neg-
atively charged as opposed to zwitterionic phospholipid spe-
cies [28], which is specially pronounced toward PG, the most
abundant anionic phospholipid in surfactants from many an-
imal species. Several lines of evidence suggest that electrostatic
interactions between SP-B and anionic phospholipids may be
important in processes occurring in surfactant metabolism. In
vitro both SP-B and PG are necessary components to recon-
stitute tubular myelin, a unique structure observed in extra-
cellular surfactant in vivo [11,12]. SP-B promotes removal of
non-DPPC components from surfactant monolayers during
compression/expansion cycling. This process is important to
enrich the ¢lms during compression in the highly tensoactive
species, DPPC. This re¢nement has been observed in the pres-
ence but not in the absence of PG [15], although the possible
e¡ect of other anionic phospholipids was not tested. A mech-
anism has recently been proposed by which selective associa-
tion of SP-B with anionic phospholipids in the surfactant
monolayer would lead to formation of three-dimensional pro-
tein^lipid aggregates excluded from the surface, via a com-
pression-driven anionic phospholipid-induced conformational
change in the protein [29]. Such a conformational transition
might produce greater exposure of epitopes as the data of the
present study suggest. Presence of anionic species in surfactant
monolayers is also necessary for SP-B to sustain high pres-
sures in compressed ¢lms, an e¡ect that may be important to
ensure stabilization of the respiratory surface until the com-
pression of the lungs is completed [17,30]. Some of these ac-
tivities could be mediated by speci¢c lipid^protein molecular
complexes, in which one or more anionic phospholipid mole-
cules could bind to speci¢c sites in SP-B. Such speci¢c binding
sites have recently been described at atomic detail for some
membrane proteins [31]. Our results show that the strongest
e¡ects in promoting exposure of epitopes in SP-B are caused
by PG, PI and PS. PG and PI are the prominent anionic
phospholipids of natural surfactant, with PG being the major
anionic phospholipid in most species and PI in some [32].
The e¡ects described here also have relevance for the opti-
mization of immunological methods to detect and quantitate
SP-B in clinical samples. Determination of SP-B levels is an
important analytical procedure to evaluate occurrence of sev-
eral respiratory pathologies including congenital SP-B de¢-
ciencies [1], or secondary alterations such as those found in
alveolar proteinosis [33], viral infections [34] or post-trans-
plantation trauma [35]. Given that the anionic phospholipids
might alter SP-B reactivity with antibodies, their proportion
in surfactant samples needs to be considered when validating
ELISA methods for SP-B measurements.
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